American Society of Hirudotherapy

Engineering ultrapotent trivalent anticoagulants through hybridisation of salivary peptides from multiple haematophagous organisms

Basic science / drug design published in Chem Sci (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportDrug DevelopmentSalivary PharmacologyMaxwell JWC et al. · Chemical science, 2025

Abstract

Haematophagous organisms are a rich source of salivary anticoagulant polypeptides that exert their activity by blocking the catalytic site and one of two positively charged exosites on the host protease thrombin. Here, we describe a molecular engineering approach to hybridise post-translationally sulfated polypeptides from different blood-feeding organisms to enhance anticoagulant activity. This led to the discovery of a triply sulfated hybrid anticoagulant, XChimera, possessing fragments from flea, leech, and fly salivary polypeptides that exhibits femtomolar inhibitory activity against thrombin. The crystallographic structure of a complex of XChimera with thrombin shows that it displays a trivalent binding mode in which it simultaneously blocks three functional sites of the protease, the active site and exosites I and II. This trivalent chimera exhibited ultrapotent anticoagulant activity in a suite of in vitro clotting assays and was also shown to possess potent in vivo antithrombotic activity in a murine model of thrombosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

Researchers hybridised sulfated salivary polypeptides from flea, leech and fly into XChimera, a triply sulfated anticoagulant that simultaneously blocks thrombin's active site and exosites I and II, with femtomolar inhibition in vitro and potent antithrombotic activity in a murine thrombosis model.

Why This Matters for Hirudotherapy

This study engineered a hybrid anticoagulant (XChimera) by combining sulfated salivary polypeptide fragments from flea, leech, and fly to achieve trivalent blockade of thrombin's active site and both exosites, yielding femtomolar inhibition. XChimera demonstrated potent anticoagulant activity in vitro and antithrombotic efficacy in a murine thrombosis model. The study is preclinical (in vitro and mouse model), and the leech component is only one of three hybridised fragments; the chimera is not a native leech secretome product and no clinical data are presented.

Citation

Reference (Vancouver style)

Maxwell JWC, Ripoll-Rozada J, Mackay AS, Alwis I, Ford DJ, Trought CBJ, et al. Engineering ultrapotent trivalent anticoagulants through hybridisation of salivary peptides from multiple haematophagous organisms. Chem Sci. 2025;16(40):18660-18672. doi:10.1039/d5sc04734j. PMID: 40959396

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.